UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000010480
Receipt No. R000012231
Scientific Title Phase I trial of biweekly Carboplatin plus nab-Paclitaxel with concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer
Date of disclosure of the study information 2013/05/01
Last modified on 2015/10/13

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Phase I trial of biweekly Carboplatin plus nab-Paclitaxel with concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer
Acronym Phase I trial of biweekly CBDCA + nab-PTX +TRT for LA-NSCLC
Scientific Title Phase I trial of biweekly Carboplatin plus nab-Paclitaxel with concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer
Scientific Title:Acronym Phase I trial of biweekly CBDCA + nab-PTX +TRT for LA-NSCLC
Region
Japan

Condition
Condition Non-small cell lung cancer
Classification by specialty
Pneumology
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To evaluate the dose limiting toxicity (DLT), estimate maximum tolerated dose (MTD) and determine recommend dose (RD) of biweekly Carboplatin plus nab-Paclitaxel with concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer. And also we evaluate the efficacy of biweekly Carboplatin plus nab-Paclitaxel with concurrent thoracic radiotherapy.
Basic objectives2 Safety
Basic objectives -Others
Trial characteristics_1 Exploratory
Trial characteristics_2
Developmental phase Phase I

Assessment
Primary outcomes Incidence of dose limiting toxicities at each dose level
Key secondary outcomes Incidence and Severity of Adverse Events
Treatment completion rate
Response Rate
2-year survival rate
Progression-free Survival
Overall Survival

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Radiotherapy: 2Gy, 5fr/week 6weeks, Total 60Gy
Carboplatin: AUC 4, day 1, 15, 29
nab-Paclitaxel: dose of each level, day 1, 15, 29
Level 1: 60 mg/m2
Level 2: 80 mg/m2
Level 3: 100 mg/m2
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
75 years-old >
Gender Male and Female
Key inclusion criteria 1) Histologically or cytologically confirmed non-small cell lung cancer.
2) Clinical Stage IIIA or IIIB.
3) No prior therapy for NSCLC.
4) V20 is 35% or less by CT simulation before enrollment.
5) At least one measurable lesion.
6) ECOG Performance status of 0-1.
7) Age of 20 to 74 years.
8) Sufficient major organ function as bellow.
*White blood cell count >= 4,000 /mm3
*Neutrophil count >= 2,000 /mm3
*Platelet count >= 100,000 /mm3
*Hemoglobin >= 9.5 g/dL
*total bilirubin <= 1.5 mg/dL
*AST <= 100 IU/L
*ALT <= 100 IU/L
*Serum creatinine <= 1.5 mg/dL
*PaO2 >= 70 Torr or more
9) Written informed consent.
Key exclusion criteria 1) Patients with T3N1.
2) Superior vena cava syndrome.
3) Contralateral hilar lymph node metastasis, malignant plueral, pericardial effusion, carcinomatous lymphangiosis.
4) Active double cancer.
5) Active infections requiring systemic treatment.
6) Severe concurrent disease (Pulmonary fibrosis or interstitial pneumonia, renal failure, hepatic failure, cerebrovascular disease, ischemic heart disease requiring treatment, arrhythmia, cardiac infarction within 6 months before enrollment, hemorrhagic peptic ulcer, poorly controlled diabetes).
7) Grade 2 or higher peripheral neuropathy.
8) Positive HBs antigen and/or HCV antibody.
9) History of Severe drug allergies.
10) Pregnant females, possibly pregnant females, females wishing to become pregnant and nursing mothers. Males that are currently attempting to produce a pregnancy.
11) Physician concludes that the patient's participation in this trial is inappropriate.
Target sample size 18

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Yukihiro Hasegawa
Organization Aomori Prefectural Central Hospital
Division name Department of Respiratory Medicine
Zip code
Address 2-1-1 Higashi Tsukurimichi, Aomori 030-8553, Japan
TEL 017-726-8111
Email yukihiro_hasegawa@med.pref.aomori.jp

Public contact
Name of contact person
1st name
Middle name
Last name Yukihiro Hasegawa
Organization Aomori Prefectural Central Hospital
Division name Department of Respiratory Medicine
Zip code
Address 2-1-1 Higashi Tsukurimichi, Aomori 030-8553
TEL 017-726-8111
Homepage URL
Email yukihiro_hasegawa@med.pref.aomori.jp

Sponsor
Institute Aomori Prefectural Central Hospital
Institute
Department

Funding Source
Organization None
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 青森県立中央病院(青森県)

Other administrative information
Date of disclosure of the study information
2013 Year 05 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2013 Year 04 Month 12 Day
Date of IRB
Anticipated trial start date
2013 Year 06 Month 01 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2013 Year 04 Month 12 Day
Last modified on
2015 Year 10 Month 13 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012231

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.